Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PureTech HealthCHIX:PRTCL -0.81%65 Debt-to-Equity is 0.06 as of Dec. 2025, which is at its 10-year median of 0.06. GuruFocus rates CHIX:PRTCL with a GF Score™ of 65/100 and a GF Value™ of £5.37 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 966 Biotechnology companies, PureTech Health ranks better than 68.32% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for PureTech Health's Debt-to-Equity or its related term are showing as below:
CHIX:PRTCl'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04 Med: 0.06 Max: 0.11
Current: 0.06
During the past 13 years, the highest Debt-to-Equity Ratio of PureTech Health was 0.11. The lowest was 0.04. And the median was 0.06.
CHIX:PRTCl's Debt-to-Equity is ranked better than 68.32% of 966
companies
in the Biotechnology industry
Industry Median: 0.16
vs CHIX:PRTCl: 0.06
PureTech Health (CHIX:PRTCl) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
PureTech Health Debt-to-Equity Related Terms
PureTech Health Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for PureTech Health's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:PRTCL vs VRTX, REGN, ALNY: Debt-to-Equity Comparison
For the Biotechnology subindustry, PureTech Health's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PureTech Health Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PureTech Health's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where PureTech Health's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PureTech Health (CHIX:PRTCL) has a Debt-to-Equity of 0.06 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on PureTech Health and its competitors. This is near median its historical median of 0.06. Over the past decade, PureTech Health's Debt-to-Equity has ranged from 0.04 to 0.11. According to the industry distribution chart, PureTech Health ranks #306 out of 966 companies in the Biotechnology industry, placing it in the top 31.7%.
Is PureTech Health's Debt-to-Equity too high?
PureTech Health's current Debt-to-Equity of 0.06 is near median its 10-year median of 0.06. Over the past 10 years, this metric has ranged from a low of 0.04 to a high of 0.11. The Biotechnology industry median Debt-to-Equity is 0.16. PureTech Health's value of 0.06 is 62.5% below this industry median. Based on the distribution chart, PureTech Health ranks #306 out of 966 companies in the Biotechnology industry, which is above the industry midpoint. Overall, PureTech Health has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PureTech Health's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, PureTech Health ranks #306 out of 966 companies for Debt-to-Equity. This puts PureTech Health in the upper half of its industry. The industry median Debt-to-Equity is 0.16. PureTech Health's value of 0.06 is 62.5% below this benchmark. Historically, PureTech Health's own Debt-to-Equity has ranged from 0.04 to 0.11 over the past decade. While the company's 10-year median is 0.06 vs. the industry median of 0.16, PureTech Health has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PureTech Health's current Debt-to-Equity of 0.06 is 62.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on PureTech Health and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PureTech Health's current Debt-to-Equity is 0.06, which is near median its own 10-year median of 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PureTech Health stock overvalued right now?
Based on GuruFocus' analysis, PureTech Health (CHIX:PRTCL) is currently considered Possible Value Trap. The stock's GF Value™ is £5.37, compared to a current price of £1.22 — trading 77.2% below its estimated fair value. The current Debt-to-Equity is 0.06, which is near median its 10-year median of 0.06 and 62.5% below the Biotechnology industry median of 0.16. PureTech Health's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For PureTech Health (CHIX:PRTCL), the current Debt-to-Equity is 0.06 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PureTech Health (CHIX:PRTCL) Overvalued in 2026?
Based on GuruFocus' analysis, PureTech Health stock appears to be undervalued.
The current stock price of £1.22 is trading 77.2% below its estimated GF Value™ of £5.37.
GuruFocus considers PureTech Health to be Possible Value Trap.
Key valuation signals for CHIX:PRTCL:
Debt-to-Equity: 0.06 (near median its 10-year median of 0.06)
GF Value™: £5.37 vs. price of £1.22 (77.2% below fair value)
Industry Position: 62.5% below the Biotechnology median (#306 of 966)
No single metric tells the full story. See the CHIX:PRTCL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.
65GF Score
Get the complete analysis for CHIX:PRTCL
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:PRTCL has been successfully added to your 
